NGNE

Neurogene Inc. (NGNE) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers Neurogene Inc.'s Form 10-Q for the quarterly period ended June 30, 2026. Neurogene is a clinical-stage biotechnology company focused on developing gene therapies for complex neurological diseases using its proprietary EXACT^TM transgene regulation technology. The company's lead program, NGN-401, is in development for the treatment of Rett syndrome. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss for the six months ended June 30, 2026, increased by $20.8 million (46%) compared to the same period in 2025, driven primarily by higher operating expenses.
• R&D Expense Growth: R&D expenses increased by $13.5 million year-over-year for the six-month period. This was primarily due to an $8.0 million increase in clinical trial costs for the NGN-401 registrational trial (Embolden) and a $3.1 million increase in Chemistry, Manufacturing, and Controls (CMC) costs.
• G&A Expense Growth: G&A expenses increased by $4.5 million year-over-year, largely attributable to a $2.7 million increase in stock-based compensation (driven by headcount growth and the vesting of performance stock units) and higher personnel costs.
• Decreased Interest Income: Interest income decreased by $1.8 million for the six-month period due to lower yields and a reduction in short-term investment balances.
• Program Deprioritization: Expenses related to the NGN-101 program for Batten disease decreased significantly as the company de-prioritized the program following the denial of an RMAT application by the FDA.

Guidance, Outlook, and Management Commentary

• Clinical Progress (NGN-401): The company completed dosing in the Phase 1/2 trial and the registrational Embolden trial for NGN-401. Positive long-term data from the Phase 1/2 trial (cutoff June 16, 2026) showed 100% of participants improved on the Clinical Global Impression-Improvement Scale and gained developmental milestones. Top-line data for the Embolden trial is expected in the second half of 2027.
• Regulatory Designations: NGN-401 holds Breakthrough Therapy, RMAT, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as PRIME designation from the EMA. The FDA has agreed to key elements of the Embolden trial design.
• Liquidity and Capital Resources: As of June 30, 2026, the company held $225.4 million in cash and investments. Management expects this to fund operations into the first quarter of 2029.
  • Subsequent Event: In July 2026, the company completed a public offering raising approximately $134.8 million in net proceeds. Following this offering, total cash and investments were approximately $360.2 million.
• Manufacturing: The company initiated its Process Performance Qualification (PPQ) campaign in July 2026 at its Houston facility, confirming commercial manufacturing scale matches clinical scale.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, regulatory delays (including potential FDA disruptions), and the complexity of gene therapy manufacturing.

Investor Verification Checklist

• Cash Runway: Verify the impact of the July 2026 capital raise on the projected cash runway into Q1 2029.
• NGN-401 Trial Status: Confirm enrollment and follow-up status for the Embolden registrational trial and the timeline for the expected H2 2027 data readout.
• Stock-Based Compensation: Review the significant increase in stock-based compensation expense and the remaining unrecognized costs ($27.8 million for options, $4.9 million for RSUs, $2.1 million for PSUs).
• NGN-101 Program: Assess the current status and potential future costs associated with the de-prioritized Batten disease program.
• Regulatory Environment: Monitor FDA leadership changes and potential impacts on the review timeline for gene therapies, given the company's reliance on expedited pathways.